University of Patras
Ανάπτυξη αναλυτικών μεθόδων για την ταυτοποίηση και ποσοτικοποίηση της δραστικής ουσίας ποσακοναζόλης σε εναιωρήματα
Abstract
dc:descriptionThe identification and quantitation of Active Pharmaceutical Ingredients’ (API) polymorphs in pharmaceutical formulations, such as suspensions, could be really challenging because of their aqueous phase and the contained low concentration of the APIs. In addition, the characterization of APIs’ polymorphs through chromatographic techniques, which could succeed low detection and quantitation limits, is impossible. Moreover, another issue, which is possible to be observed during the identification process of APIs’ polymorphism in pharmaceutical suspensions, is the quick polymorphic conversion of the APIs in the formulation.An API that is usually administered to patients as a pharmaceutical suspension is posaconazole. Posaconazole is commercially available as an oral suspension 40 mg/mL, as a 18 mg/mL sterile concentrate for solution for intravenous infusion and as 100 mg gastro-resistant tablets. It is a novel member of the triazole antifungal drugs, belonging to their second generation and it has the widest antifungal spectrum of all antifungal medicines. Until recently, 14 different forms of posaconazole have been recorded; more specifically, polymorphs I, II, III, IV, V, II-S, Y, A, S, N, an isopropanol solvate, a methanol solvate and a dioxane-water solvate, as well as the amorphous posaconazole have been described in literature. Among these forms, the polymorphic form I is the most stable and it is used for manufacturing posaconazole pharmaceutical suspensions.The direct analysis of posaconazole oral suspensions via X-Ray Powder Diffraction (XRPD) and Raman Spectroscopy leaded to diffractograms and Raman spectra of low quality; thus, the identification of API’s polymorphism was not possible. For this purpose, a method was developed for enhancing the signal-to-noise ratio in both techniques. According to this method, posaconazole oral suspensions were centrifuged and the precipitates were isolated. Subsequently, the precipitates were covered with a low-density polyehthylene (LDPE) cling film and their XRPD diffractograms and Raman spectra were recorded. Hence, posaconazole in its oral suspensions was identified as form-S. The search of the reason of the transformation of the initial posaconazole polymorph I to posaconazole polymorph S leaded to the conclusion that water is responsible for the polymorphic conversion. Furthermore, it was found that even the simple contact of posaconazole polymorph I with water triggers the conversion to form-S to a great extent. Succeeding complete wetting of posaconazole polymorph I with water, by homogenizing the water dispersion in a sonication bath for at least 10 min, resulted in a complete conversion to polymorph S. After filtration of the aqueous dispersion, the pure polymorph S was isolated and it was characterized by XRPD, Raman Spectroscopy, Attenuated Total Reflectance (ATR), Optical Microscopy, Differential Scanning Calorimetry (DSC) and Thermogravimetric Analysis (TGA).The XRPD diffractograms of posaconazole polymorphs S and I were used to determine their crystal lattices by applying the dichotomy method via PreDICT software. Both polymorphs were found to adopt the monoclinic crystal lattice. The dimensions of the unit cell of the crystal lattice of polymorph S were found a = 12.3799 Å, b = 6.3053 Å and c = 23.1258 Å, the angle β = 93.140ο and its volume V = 1802.47 Å3, while the axes’ dimensions of the unit cell of the crystal lattice of polymorph I were calculated equal to a = 12.5355 Å, b = 6.3481 Å and c = 22.7796 Å, the angle β = 96.387ο and its volume V = 1801.48 Å3. In Optical Microscopy, polymorph S was observed to form a net of crystals, connected loosely with each other, while they are surrounded by water molecules. The analysis of posaconazole polymorph S through DSC and TGA leaded to the conclusion that form-S is a hydrated form. Moreover, stoichiometric mixtures of posaconazole polymorph I with water were prepared and it was found that at least 2 mol water per 1 mol posaconazole polymorph I are required for the polymorphic conversion to form-S.The quantitation of polymorphs S and I via XRPD followed. For this purpose, posaconazole standard oral suspensions were prepared by diluting a 40 mg/mL initial oral suspension with Placebo. Then, the standard suspensions were centrifuged and the precipitates were isolated. For the construction of the calibration curve of polymorph S, the precipitates were covered with LDPE cling film, while for the calibration curve of polymorph I the precipitates were dried overnight, after removing the cling film, so that the conversion to the initial form I would be completed. After the analysis of the precipitates the characteristic peaks of polymorph S at 10.2o 2θ, polymorph I at 9.9o 2θ and the excipient titanium dioxide (TiO2), which was used as an internal standard, at 25.3o 2θ were integrated and the ratios of the peak intensities of each polymorph to the peak intensity of TiO2 were calculated, i.e. I10.2/I25.3 for polymorph S and I9.9/I25.3 for polymorph I. By using the optical evaluation method in the XRPD patterns, the detection limit (DL) of polymorph S was found equal to 2.0 mg/mL, while the quantitation limit (QL) was calculated equal to 6.0 mg/mL. For polymorph I, it was found DL = 3.0 mg/mL and QL = 9.0 mg/mL. The concentration of polymorph S in a 25 mg/mL posaconazole oral suspension was determined equal to (23.3 ± 1.7) mg/mL, while the concentration of polymorph I was found (21.6 ± 1.0) mg/mL. In a 40 mg/mL posaconazole oral suspension, which was found as a mixture of polymorphs S and I, their concentrations were found (22.1 ± 1.7) mg/mL and (19.6 ± 1.0) mg/mL, respectively. However, both XRPD quantification methods are lacking of accuracy, repeatability and intermediate precision, which is caused because of the preferred orientation of the crystals of the two polymorphs of the API and TiO2.The issue of preferred orientation was solved by using Raman spectroscopy. For the analysis, a special equipment was employed for the rotation of the sample. The peaks of polymorphs S and I at 738 cm-1 and 745 cm-1, respectively and the peak of TiO2 at 393 cm-1 were integrated and the ratios of the peak intensities of each polymorph to the peak intensity of TiO2 were calculated, i.e. I738/I393 for polymorph S and I745/I393 for polymorph I. The limits of detection and quantitation were calculated from the calibration curves data for polymorph S, DL = 1.9 mg/mL and QL = 5.9 mg/mL, while for polymorph I, DL = 2.2 mg/mL and QL = 6.6 mg/mL. The concentrations of polymorphs S and I in the 25 mg/mL posaconazole oral suspension were determined equal to (24.1 ± 0.5) mg/mL και (25.6 ± 0.6) mg/mL, respectively, while in the 40 mg/mL posaconazole oral suspensions, in which the API was identified as a mixture of both polymorphs, the concentrations of polymorphs S and I were found (25.4 ± 0.5) mg/mL και (14.7 ± 0.6) mg/mL, respectively. The developed quantitation methods for polymorphs S and I via Raman Spectroscopy were validated and it was found that they are characterized by excellent accuracy, precision (repeatability and intermediate precision), sensitivity, specificity and robustness.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Lykouras, Michail
- Λυκούρας, Μιχαήλ
Subjects
dc:subject × 28- Φαρμακευτική ανάλυση
- Εναιωρήματα
- Ποσακοναζόλη
- Πολυμορφισμός
- Ένυδρη μορφή
- Ταυτοποίηση
- Ποσοτικοποίηση
- Pharmaceutical analysis
- Suspensions
- Posaconazole
- Polymorphism
- Hydrate
- Identification
- Quantification
- Χημεία
- Φυσικές Επιστήμες
- Αναλυτική χημεία
- Βασική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ανακάλυψη και Ανάπτυξη φαρμάκων
- Φαρμακολογία και Φαρμακευτική
- Chemical Sciences
- Natural Sciences
- Analytical Chemistry
- Basic Medicine
- Medical and Health Sciences
- Drug Discovery
- Pharmacology and Pharmacy
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/52533